REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 796-805

  Stuart, Robert K ^a   Cripe, Larry D ^b   Maris, Michael B ^c   Cooper, Maureen A ^d,o   Stone, Richard M ^e   Dakhil, Shaker R ^f   Turturro, Francesco ^g,l   Stock, Wendy ^h   Mason, James ⁱ   Shami, Paul J ^j   Strickland, Stephen A ^k   Costa, Luciano J ^a   Borthakur, Gautam ^l   Michelson, Glenn C ^m   Fox, Judith A ^m   Leavitt, Richard D ⁿ   Ravandi, Farhad ^l  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Rocky Mountain Blood and Marrow Transplant Program   (United States)

^d St Francis Hospital   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Cancer Center of Kansas   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ SCRIPPS CLINIC   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m Sunesis Pharmaceuticals Inc   (United States)

ⁿ PharmaPacific Inc ^*  (United States)

^o Southwest Oncology   (United States)

more..

Author keywords

Acute myeloid leukaemia; Elderly; Newly diagnosed; Topoisomerase II inhibitor; Vosaroxin

Indexed keywords

VOSAROXIN; ANTINEOPLASTIC AGENT; NAPHTHYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CHILL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRACKLE; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INCIDENCE; INFECTION; INSOMNIA; LEUKOPENIA; MALE; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PETECHIA; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NAPHTHYRIDINES; PROGNOSIS; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT OUTCOME;

EID: 84924020604     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13214     Document Type: Article

References (21)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481-3485.
2. Blum, W., Garzon, R., Klisovic, R.B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., Mickle, J., Devine, H., Kefauver, C., Devine, S.M., Chan, K.K., Heerema, N.A., Bloomfield, C.D., Grever, M.R., Byrd, J.C., Villalona-Calero, M., Croce, C.M. & Marcucci, G. (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences USA, 107, 7473-7478.
3. Burnett, A., Wetzler, M. & Lowenberg, B. (2011) Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology, 29, 487-494.
4. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R., Bloomfield, C.D. & International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
5. Evanchik, M.J., Allen, D., Yoburn, J.C., Silverman, J.A. & Hoch, U. (2009) Metabolism of (+)-1, 4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1, 8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metabolism and Disposition, 37, 594-601.
6. Gewirtz, D.A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727-741.
7. Green, S.J. & Dahlberg, S. (1992) Planned versus attained design in phase II clinical trials. Statistics in Medicine, 11, 853-862.
8. Hawtin, R.E., Stockett, D.E., Byl, J.A., McDowell, R.S., Nguyen, T., Arkin, M.R., Conroy, A., Yang, W., Osheroff, N. & Fox, J.A. (2010a) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One, 5, e10186.
9. Hawtin, R.E., Stockett, D.E., Wong, O.K., Lundin, C., Helleday, T. & Fox, J.A. (2010b) Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget, 1, 606-619.
10. Hoch, U., Lynch, J., Sato, Y., Kashimoto, S., Kajikawa, F., Furutani, Y. & Silverman, J.A. (2009) Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemotherapy and Pharmacology, 64, 53-65.
11. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J. & Estey, E. (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 106, 1090-1098.
12. Kantarjian, H., Ravandi, F., O'Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., Jabbour, E., Wierda, W., Kadia, T., Pierce, S., Shan, J., Keating, M. & Freireich, E.J. (2010) Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 116, 4422-4429.
13. Kantarjian, H.M., Thomas, X.G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.P., Chou, W.C., Buckstein, R., Cermak, J., Kuo, C.Y., Oriol, A., Ravandi, F., Faderl, S., Delaunay, J., Lysak, D., Minden, M. & Arthur, C. (2012a) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology, 30, 2670-2677.
14. Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., Stock, W., Claxton, D., Goldberg, S.L., Arellano, M., Strickland, S.A., Seiter, K., Schiller, G., Jabbour, E., Chiao, J. & Plunkett, W. (2012b) Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. The Lancet Oncology, 13, 1096-1104.
15. Lancet, J.E., Ravandi, F., Ricklis, R.M., Cripe, L.D., Kantarjian, H.M., Giles, F.J., List, A.F., Chen, T., Allen, R.S., Fox, J.A., Michelson, G.C. & Karp, J.E. (2011) A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia, 25, 1808-1814.
16. Menzin, J., Lang, K., Earle, C.C., Kerney, D. & Mallick, R. (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine, 162, 1597-1603.
17. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185-229.
18. Pollyea, D.A., Kohrt, H.E. & Medeiros, B.C. (2011) Acute myeloid leukaemia in the elderly: a review. British Journal of Haematology, 152, 524-542.
19. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
20. Vincent, G., Velkoff, V. & Bureau, U.C. (2010) The Next Four Decades: The Older Population in the United States: 2010 to 2050. US Department of Commerce, Economics and Statistics Administration, US Census Bureau, Washington, DC.
21. Walsby, E.J., Coles, S.J., Knapper, S. & Burnett, A.K. (2011) The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica, 96, 393-399.